Interestingly, preclinical studies have suggested that oncogenic PIK3CA driven the development of breast cancer (Liu et al., 2011; Utermark et al., 2012), and the PI3Kα-selective inhibitors shown more effective and more tolerable toxicity profile in clinical trails (Juric et al., 2018; Mayer et al., 2017). Here, PIK3CA is linked to breast carcinoma.